OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) – Opportunity Analysis and Forecasts to 2017

Publisher Name :
Date:30-Sep-2013
No. of pages: 128

GlobalData has released its new Opportunity Analyzer report, “Nonalcoholic Steatohepatitis (NASH) – Opportunity Analysis and Forecasts to 2017”. The NASH market is currently deserted and awaits its first NASH-specific therapy. With novel mechanism of action awaiting approval such as: Genfit’s PPAR agonist, GFT505 and Intercept Pharmaceuticals/Dainippon Sumitomo Pharma’s FXR agonist, Obeticholic Acid. These compounds will race to be the first approved therapy thus claiming first in class.

Scope

  • Overview of NASH, including epidemiology, etiology, symptoms, diagnosis, pathology and disease management.
  • Analysis of the current and future market competition in the global NASH therapeutics market.
  • Pipeline analysis: comprehensive data split across Phase II/IIb, emerging trends and mechanisms of action under development, including: oral Proliferator Activated Receptor alpha, delta (PPARa,d) agonist, oral Farnesoid X Receptor (FXR) agonist, subcutaneous Lysyl Oxidase-Like 2 (LOXL2) inhibitor and subcutaneous Glucagon-like Peptide-1 (GLP-1) agonist.
  • Annualized NASH therapeutics market forecast, annual cost of therapy and treatment usage pattern data from 2012-2017.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • Key topics covered include strategic clinical and commercial benchmarking assessment of the pipeline and standard of care, market outlook, R&D strategies, and unmet needs for the NASH therapeutics market.

Reasons To Buy

Develop business strategies and perform superior market quantification analysis by:

  • Understanding the trends shaping and driving the global NASH Therapeutics market.
  • Understanding treatment preferences of physicians in disease state and across treatment flow.
  • Accessing market sizing, forecasts and quantified growth opportunities in the global NASH Therapeutics market till 2017.
  • Quantifying patient population in the global NASH Therapeutics market to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
  • Performing benchmarking analysis and growth opportunities against currently marketed products.
  • Identifying market entry points based on safety, efficacy, and pricing parameters.
  • Assessing competitiveness of products in market by understanding the strength and weakness of current competition.
  • Develop and design your in-licensing and out-licensing strategies by
  • Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
  • Assessing strength of pipeline based on first in class and lifecycle management of products.
  • Analyze the potential impact of novel oral therapies such as Genfit’s GFT505 on the NASH treatment paradigm.
  • Track drug sales in the global NASH Therapeutics market from 2012 to 2017.
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
  • What’s the next big thing in the global NASH Therapeutics market landscape? Identify, understand, and capitalize.

OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) – Opportunity Analysis and Forecasts to 2017

Table of Contents

1 Table of Contents 7
1.1 List of Tables 11
1.2 List of Figures 12

2 Introduction 13
2.1 Catalyst 13

3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 15
3.2 Symptoms 19

4 Epidemiology 21
4.1 Disease Background 21
4.2 Risk Factors and Comorbidities 22
4.2.1 Increased age is associated with a worsened disease progression, prognosis, and mortality 22
4.2.2 Being a male is an independent risk factor in morbidly obese NASH cases 23
4.2.3 Metabolic conditions, such as type 2 diabetes, considerably increase the risk of NASH 25
4.3 Global and Historical Trends 26
4.3.1 US 28
4.3.2 5EU 29
4.4 Forecast Methodology 31
4.4.1 Sources Used 33
4.4.2 Forecast Assumptions and Methods 35
4.4.3 Sources Not Used 38
4.5 Epidemiology Forecast of Nonalcoholic Steatohepatitis (2012-2022) 39
4.5.1 Total Prevalent Cases of Nonalcoholic Steatohepatitis 39
4.5.2 Age-Specific Prevalent Cases of Nonalcoholic Steatohepatitis 41
4.5.3 Sex-Specific Prevalent Cases of Nonalcoholic Steatohepatitis 44
4.5.4 Age-Standardized Prevalence of Nonalcoholic Steatohepatitis 45
4.6 Discussion 46
4.6.1 Conclusions on Epidemiological Trends 46
4.6.2 Limitations of the Analysis 47
4.6.3 Strengths of the Analysis 48

5 Current Treatment Options 49
5.1 Overview 49
5.2 Product Profiles - Major Off-Label Brands 52
5.2.1 Vitamin E (numerous generics) 52
5.2.2 Pioglitazone (Actos) 56

6 Unmet Needs Assessment and Opportunity Analysis 61
6.1 Overview 61
6.2 Unmet Needs Analysis 63
6.2.1 Lack of Approved Therapies 63
6.2.2 Identification of Biomarkers for Early Diagnosis and Endpoints 64
6.2.3 Physician Awareness Due to Understanding of Pathophysiology 65
6.3 Opportunity Analysis 65
6.3.1 Therapies with Targeted MOA to NASH 65
6.3.2 Better Models to Understand Drug Efficacy 65
6.3.3 Future Tool to Measure Fibrosis in NASH Patients 66

7 R&D Strategies 67
7.1 Overview 67
7.1.1 Understanding Multiple Factors of NASH 67
7.1.2 Potential for a Personalized Approach 68
7.2 Clinical Trial Design 69
7.2.1 Differences in Diagnosis, Monitoring, and Sensitive Imaging Techniques Are Needed 70
7.2.2 Patient Recruitment Issues 70
7.2.3 Appropriate Endpoints 71
7.2.4 Clinical Regulatory Guidelines 72

8 Pipeline Assessment 74
8.1 Overview 74
8.2 Promising Drugs in Clinical Development 75
8.2.1 GFT505 76
8.2.2 Obeticholic Acid (INT-747) 80
8.2.3 Simtuzumab (Formerly GS-6624) 84
8.2.4 Liraglutide (Victoza) 88
8.3 Innovative Early-Stage Approaches 92
8.3.1 Targeting Cytokines 93

9 Pipeline Valuation Analysis 95
9.1 Clinical Benchmark of Key Pipeline Drugs 95
9.2 Commercial Benchmark of Key Pipeline Drugs 98
9.3 Competitive Assessment 100
9.4 Top-Line Five-Year Forecast 101
9.4.1 US 105
9.4.2 5EU 106

10 Appendix 108
10.1 Bibliography 108
10.2 Abbreviations 116
10.3 Methodology 119
10.4 Forecasting Methodology 119
10.4.1 Diagnosed NASH Patients 119
10.4.2 Percent Drug-Treated Patients 120
10.4.3 Drugs Included in Each Therapeutic Class 120
10.4.4 Launch Dates 121
10.4.5 General Pricing Assumptions 121
10.4.6 Individual Off-Label Drug Assumptions 122
10.4.7 Pricing of Pipeline Agents 122
10.5 Physicians and Specialists Included in this Study 123
10.6 About the Authors 124
10.6.1 Author 124
10.6.2 Epidemiologist 125
10.6.3 Global Head of Healthcare 126
10.7 About GlobalData 127
10.8 Disclaimer 127

List of Tables

Table 1: Symptoms of NASH 19
Table 2: Risk Factors and Comorbidities for NASH 22
Table 3: Reported Prevalence of NASH in the US and 5EU 27
Table 4: Reported Prevalence of NAFLD in the US and 5EU 27
Table 5: 6MM, Sources of Prevalence Data Used in the NASH Epidemiological Forecast 32
Table 6: 6MM, Prevalent Cases of NASH, Ages ≥ 20 Years, Men and Women, N, Selected Years, 2012-2022 40
Table 7: 6MM, Prevalent Cases of NASH, By Age*, Men and Women, N (Row %), 2012 42
Table 8: 6MM, Prevalent Cases of NASH, Ages ≥ 20 Years, By Sex, N (Row %), 2012 44
Table 9: Off-Label Treatments for NASH 51
Table 10: Product Profile - Vitamin E 53
Table 11: Vitamin E SWOT Analysis in NASH, 2013 55
Table 12: Product Profile - Pioglitazone 57
Table 13: Pioglitazone SWOT Analysis in NASH, 2013 60
Table 14: Overall Unmet Needs in NASH - Current Level of Attainment 62
Table 15: Current Clinical Trial Design of Key Pipeline Drugs for NASH, 2013 73
Table 16: NASH - Mid-Late-Stage Pipeline, 2013 75
Table 17: Product Profile - GFT505 77
Table 18: GFT505 SWOT Analysis, 2013 79
Table 19: Product Profile - Obeticholic Acid (INT-747) 81
Table 20: Obeticholic Acid (INT-747) SWOT Analysis, 2013 83
Table 21: Product Profile - Simtuzumab 85
Table 22: Simtuzumab SWOT Analysis, 2013 87
Table 23: Product Profile - Liraglutide 89
Table 24: Liraglutide Safety Profile from the LEAD Program 90
Table 25: Liraglutide SWOT Analysis, 2013 91
Table 26: Early-Stage Pipeline Products in NASH, 2013 93
Table 27: Clinical Benchmark of Key Pipeline Drugs for NASH, 2013 97
Table 28: Commercial Benchmark of Key Pipeline Drugs for NASH, 2013 99
Table 29: Top-Line Sales Forecasts ($m) for NASH, 2012-2017 102
Table 30: Key Events Impacting Sales for NASH, 2017 103
Table 31: NASH Market: US and 5EU - Drivers and Barriers, 2012-2017 104
Table 32: Key Launch Dates 121

List of Figures

Figure 1: Two-Hit and Multiple-Hits Theories in NASH 16
Figure 2: Distinct-Hit Pathogenesis in NASH 18
Figure 3: Stages of Liver Disease 20
Figure 4: 5EU, Prevalence of NAFLD and Obesity, Ages ≥ 20 Years, Men and Women, % 30
Figure 5: 6MM, Prevalent Cases of NASH, Ages ≥ 20 Years, Men and Women, N, Selected Years, 2012-2022 40
Figure 6: 6MM, Prevalent Cases of NASH, By Age*, Men and Women, N, 2012 43
Figure 7: 6MM, Prevalent Cases of NASH, Ages ≥ 20 Years, By Sex, N, 2012 45
Figure 8: Liver Biopsy to Confirm NASH 50
Figure 9: Competitive Assessment of Mid-Stage Pipeline Agents in NASH, 2012-2017 76
Figure 10: Competitive Assessment of Mid-Stage Pipeline Agents in NASH, 2012-2017 100
Figure 11: Global Sales for NASH by Region, 2012-2017 103

  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Chronic Lymphocytic Leukemia (CLL) Treatment Market worth $3.3 billion by 2018
  • New Entrants to Boost Chronic Lymphocytic Leukemia Treatment Market Value to $3.3 Billion by 2018, says GlobalData. The introduction of several new drugs will accelerate growth in the Chronic Lymphocytic Leukemia (CLL) treatment market, from $1.4 billion in 2013 to …

  • Croatia Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 102
    BMI View: Heavy price cuts and margin restrictions within the pharmaceutical supply chain threaten to cause drug shortages and weaken the supply chain within Croatia, with product withdrawals expected and the HZZO braced for revolt from pharmacies and wholesalers. We forecast weak pharmaceutical market growth over the next decade, in light of Croatia's acceding to EU pressure to rein in its budget deficit. Liquidity issues and payment terms will remain unfavourable in 2014, but with Croatia's ec......
  • Kenya Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 106
    BMI View: Investment into Kenya's healthcare sector by pharmaceutical and medical device companies is an advisable business strategy - as highlighted by the high growth forecast in healthcare spending between 2013 and 2018. However, we note that there are downside risks to our forecast, including government inefficiencies and the out-of-pocket characteristics of the market, which will act as challenges for companies looking for a rapid return on investment. Headline Expenditure Projections ? Pha......
  • Latvia Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 107
    BMI View: Latvia's macroeconomic environment continues to improve at the same time as smooth transitions to a new currency and new Prime Minister. Market growth forecasts are strong although the country will continue to present a modest opportunity to larger multinational companies on account of its relatively small market size. Meanwhile, tensions between Ukraine and Russia may provide challenges for local manufacturers looking towards exports to Russia to boost revenue. Headline Expenditure Pr......
  • Mexico Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 144
    BMI View: The lack of a unified reimbursement system, the absence of widespread private health insurance, relatively low healthcare spending and the promotion of generic drugs in Mexico will continue to undermine revenue-generating opportunities for innovative drugmakers. However, over the long term, healthier fiscal revenue due to energy reform will encourage the Mexican government to further increase public spending on medical services and improve national healthcare standards.. Headline Expen......
  • Thailand Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 115
    BMI View: Thailand offers several revenue earning opportunities to drugmakers due to its ageing population and the presence of a universal healthcare system that provides the population with access to healthcare. However cost containment policies and delays in patent approvals limit the attractiveness of the country to multinational pharmaceutical firms. Headline Expenditure Projections ? Pharmaceuticals: THB142.5bn (USD4.64bn) in 2013 to THB146.5bn (USD4.5bn) in 2014; +2.8% in local currency te......
  • Algeria Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 101
    BMI View: The Algerian government's aspirations to rebalance the pharmaceutical trade deficit and promote local generic production, whilst enhancing the country's competitiveness by stimulating the innovative biopharmaceutical industry as a strategic sector in the economy, will continue throughout Q414. A new memorandum of understanding between Pharmaceutical Research and Manufacturers of America (PhRMA) and Algeria's government indicates additional steps towards encouraging foreign direct inves......
  • Zambia Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 61
    BMI View: The disparity between urban and rural healthcare provision in Zambia is showing signs of being addressed, with the recent opening of the first ever hospital to serve the district of Chienge. This, along with ongoing governmental training initiatives aimed at improving the skills of Zambian healthcare professionals, is likely to attract talent to the country. That said, speculation over President Sata's ill health, along with delays in the construction of 650 healthcare clinics across t......
  • 2014 Market Research Report on Global Seaweed Fertilizer Industry
    Published: 19-Aug-2014        Price: US $3600 Onwards        Pages: 182
    This is a professional and depth research report on Global Seaweed Fertilizer industry. The report firstly introduced Seaweed Fertilizer basic information included Seaweed Fertilizer definition classification application industry chain structure industry overview;Then introduce North America (United States Canada etc) Europe (Ireland UK etc) Asia (China India etc) Rest of World Key players 2009-2014 Seaweed Fertilizer Capacity Production Price Cost Gross Production Value Gross Margin etc Dat......
  • 2014 Market Research Report on Global Glucose Meter Industry
    Published: 19-Aug-2014        Price: US $3600 Onwards        Pages: 321
    This is a professional and depth research report on Global Glucose Meter industry. The report firstly introduced Glucose Meter basic information included Glucose Meter definition classification application industry chain structure industry overview;Then introduce North America (United States Canada Mexico etc) Europe (Germany France United Kingdom Italy Spain etc) Asia (China Japan India Korea etc) Rest of World (Australia South America Middle East and Africa etc) Key players 2009-2014 Gluco......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs